“…(Hoshi, et al, 2004) IgG (Rituximab, Trastuzumab) Commercial PNGase F TOF (3-AA), CE Method for monitoring glycosylation in pharmaceuticals based on capillary electrophoresis with structural confirmation by MALDI-TOF MS (Kamoda, et al, 2004) IgG (Sriraman, et al, 2004) IgG 1 (Human) Rat hybridoma or CHO Hydrazine MALDI, HPLC, Glycans (2-AP), Absence of fucose but not presence of galactose or bisect enhances cellular toxicity (Shinkawa, et al, 2003) IgG 3 M o u s e Hydrazine, PNGase F R-TOF (+ve) (DHB), ESI, MS/MS, Glycans Effect of buffer and pH on production. (Müthing, et al, 2003) IgG 4 (Human) CHO-S cells Trypsin TOF (CHCA), Glycopeptides Glycosylation (high-mannose, truncated complex) not significantly affected by anti-mitotic agent (Tait, et al, 2004) KDEL-tagged cPIPP antibody Structural characterization (Fujiyama, et al, 2004) Lecithin:cholesterol acyltransferase (Lane, et al, 2004) Luteinizing hormone (Human) CHO cells Hydrazine R -TOF (DHB, CMBT), ESI, Ion trap, Glycans (2-AB) Structural determination of complex glycans and method development (Gervais, et al, 2003) MFE-CP…”